Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Common Equity: 2011-2024

Historic Common Equity for RedHill Biopharma (RDHL) over the last 10 years, with Dec 2024 value amounting to -$4.7 million.

  • RedHill Biopharma's Common Equity fell 326.34% to -$4.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$4.7 million, marking a year-over-year decrease of 326.34%. This contributed to the annual value of -$4.7 million for FY2024, which is 326.34% down from last year.
  • RedHill Biopharma's Common Equity amounted to -$4.7 million in Q4 2024, which was down 7,777.05% from $61,000 recorded in Q2 2024.
  • RedHill Biopharma's Common Equity's 5-year high stood at $53.0 million during Q1 2021, with a 5-year trough of -$48.4 million in Q4 2022.
  • In the last 3 years, RedHill Biopharma's Common Equity had a median value of -$5.2 million in 2022 and averaged -$16.3 million.
  • Its Common Equity has fluctuated over the past 5 years, first slumped by 645.35% in 2022, then surged by 104.27% in 2023.
  • Over the past 5 years, RedHill Biopharma's Common Equity (Quarterly) stood at $13.9 million in 2020, then plummeted by 35.99% to $8.9 million in 2021, then tumbled by 645.35% to -$48.4 million in 2022, then skyrocketed by 104.27% to $2.1 million in 2023, then tumbled by 326.34% to -$4.7 million in 2024.
  • Its Common Equity stands at -$4.7 million for Q4 2024, versus $61,000 for Q2 2024 and $2.1 million for Q4 2023.